Nektar Therapeutics Offers A High-Potential But Controversial Pipeline [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
Summary It has been a while since I updated my thoughts on Nektar Therapeutics ( NKTR ), and a lot has happened with this biotech over the past year , including a huge development deal with Bristol-Myers ( BMY ), mixed trial data at ASCO, and ongoing progress with additional compounds in the oncology pipeline. On top of all that, Nektar has a pain asset with potentially impressive upside, an exciting early-stage anti-inflammatory asset, and a significant amount of cash. Nektar shares sold off hard after the disappointing ASCO results, but have since recovered 40%. At this price, I don’t necessarily think Nektar is seriously undervalued relative to the development risk. That’s a key caveat, though, as better clinical data on the NKTR-214 (or ‘214) melanoma program at the November SITC could restore some bullishness here and there is a lot of potential value in ‘214, NKTR-358, NKTR-262, and NKTR-255 that could be unlocked with future clinical successes. A Year Lat
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test [Seeking Alpha]Seeking Alpha
- Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 3/4/24 - Miss
NKTR
Sec Filings
- 4/17/24 - Form 8-K
- 3/19/24 - Form D
- 3/15/24 - Form SC
- NKTR's page on the SEC website